Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Luger, S. M.; Sun, Z.; Loghavi, S.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Pratz, K. W.; Litzow, M. |
| Abstract Title: | Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML) |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577160401125 |
| DOI: | 10.1182/blood-2019-128377 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1309 -- Source: Wos |
